Patients and caregivers should be included as equal partners in the drug development process, particularly for rare conditions where limitations on what we know about a disease may exist. Rare disease nonprofit organizations can drive research and data collection efforts that may be leveraged to guide researchers toward meaningful outcomes and patient-centric clinical trial designs.
Join us to learn how community-led collaborations with industry and academic researchers can accelerate drug development by encouraging data sharing and collaborative engagement with initiatives, such as the Rare Disease Cures Accelerator – Data and Analytics Platform (RDCA-DAP). Discover how rare disease nonprofits can play a role in advancing treatments and cures for their communities.
